| Mrs Heather Dawn Perkins, | |
|
1412 N 2nd St, Atchison, KS 66002-1203 | |
| (913) 367-4879 | |
| Not Available |
| Full Name | Mrs Heather Dawn Perkins |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 1412 N 2nd St, Atchison, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679332498 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 2333405 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Heather Dawn Perkins, 1412 N 2nd St, Atchison, KS 66002-1203 Ph: (913) 367-4879 | Mrs Heather Dawn Perkins, 1412 N 2nd St, Atchison, KS 66002-1203 Ph: (913) 367-4879 |
News Archive
FASgen Inc. announced it has successfully expanded the potential use for its serum FAS (fatty acid synthase) ELISA diagnostic research test, FAS-Detect ELISA for the identification of Non-Alcoholic Steatophepititis (NASH).
Concord Medical Services Holdings Limited, a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, is pleased to announce that its subsidiary, Medstar Leasing Co., Ltd, has signed a contract with IBA for the purchase, installation and maintenance of a proton therapy system, which will be installed at Beijing Proton Medical Center.
The Boston-based environmental research group reported today that even though we spend only a tiny portion of our day commuting, it's during the commute that we receive more than half our overall exposure to deadly fine particle pollution.
InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has received 510(k) clearance from the United States Food and Drug Administration to market the LipiScan IVUS Coronary Imaging System. LipiScan IVUS is the first cardiac catheter to combine intravascular ultrasound and near-infrared spectroscopy to help cardiologists identify and characterize the plaques that complicate stenting and are associated with acute coronary events.
The extent to which protein targets are modulated by drugs or small molecule compounds depends on a number of factors, including the expression levels of the target, the effective concentration of the compound, and the time needed for the compound to perturb the target. To address these restrictions, researchers Abassi et al. (1) have devised a live cell morphological profiling approach for dynamic monitoring of the effect of small molecule compounds that was based on impedance measurement of cells with the xCELLigence RTCA System of Roche Applied Science.
› Verified 6 days ago
Nicole Mcdevitt, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1412 N 2nd St, Atchison, KS 66002 Phone: 913-246-3560 | |
Alexis Cairo, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 1412 N 2nd St, Atchison, KS 66002 Phone: 913-367-4879 Fax: 913-367-0240 |